Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2944876;   Drug: Exenatide extended-release;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2014

Go Girls! Fitness Support Group Intervention Effectiveness Study

Conditions:   Polycystic Ovary Syndrome;   Abnormal Weight Gain;   Excess Weight;   Insulin Resistance;   Premature Adrenarche;   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Go Girls! Fitness Support Group
Sponsors:   University of Virginia;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified April 2014

Can Vitamin D Supplementation Prevent Type 2 Diabetes?

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Vitamin D;   Dietary Supplement: Placebo
Sponsors:   Monash University;   Victoria University, Australia;   University of Auckland, New Zealand
Not yet recruiting - verified April 2014

Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Liraglutide;   Drug: Placebo
Sponsors:   Vastra Gotaland Region;   Novo Nordisk A/S
Active, not recruiting - verified April 2014

Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ertugliflozin 15 mg
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Not yet recruiting - verified April 2014

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Condition:   Healthy
Interventions:   Biological: HEPLISAV;   Biological: Engerix-B
Sponsor:   Dynavax Technologies Corporation
Recruiting - verified April 2014

A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2409021;   Drug: Sitagliptin;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2014

Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin

Condition:   Diabetes Mellitus Type 2
Interventions:   Other: Questionnaire administration;   Other: Laboratory biomarker analysis
Sponsors:   University Hospital, Basel, Switzerland;   University of Basel;   Solothurner Spitäler AG
Recruiting - verified April 2014

RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:  
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   University of Oxford;   Oxford University Hospitals NHS Trust;   University of Dundee;   NHS Tayside
Recruiting - verified April 2014

Effect of Implantable Contraception on Type-2 DM and Metabolic Syndrome in Women With History of Gestational DM

Conditions:   Diabetes Mellitus;   Metabolic Syndrome
Intervention:   Device: progestin implant
Sponsor:   Mahidol University
Active, not recruiting - verified April 2014

Is There Room for Butter in a Healthy Diet?

Condition:   Atherosclerosis
Interventions:   Other: Danish butter;   Other: Olive oil
Sponsors:   University of Copenhagen;   The Danish Dairy Research Foundation, Denmark
Completed - verified April 2014

Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.

Condition:   Focus Type 2 Diabetes Related Chronic Kidney Disease
Intervention:   Behavioral: Exercise
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified April 2014

PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   Hypertriglyceridemia
Interventions:   Drug: Metformin Eicosapentaenoate;   Drug: Metformin HCl and Vascepa
Sponsor:   Thetis Pharmaceuticals LLC
Recruiting - verified April 2014

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin Peglispro;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified April 2014

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Not yet recruiting - verified April 2014

Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: 6-day Continuous Glucose Monitoring System
Sponsor:   University of Malaya
Recruiting - verified April 2014

Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

Condition:   Metabolic Syndrome X
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   University of Guadalajara
Not yet recruiting - verified April 2014

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec/liraglutide;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community

Condition:   Diabetes
Interventions:   Behavioral: Experimental: Diabetes Self Management;   Behavioral: General Health Education
Sponsors:   University of North Carolina, Greensboro;   National Institutes of Health (NIH)
Recruiting - verified April 2014

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Not yet recruiting - verified April 2014

Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial

Conditions:   Hypertension;   Metabolic Syndrome
Interventions:   Behavioral: Comprehensive Lifestyle Modification;   Behavioral: DASH
Sponsors:   Universität Duisburg-Essen;   Kliniken Essen-Mitte;   Immanuel Hospital Berlin, Berlin, Germany;   Charité University Medical Center, Berlin, Germany;   University of Witten/Herdecke
Recruiting - verified April 2014

A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY2409021;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test

Conditions:   Genetics;   Metabolism;   Type 2 Diabetes
Interventions:   Other: Mixed Meal Tolerance Test;   Drug: Metformin
Sponsors:   Massachusetts General Hospital;   Instituto Carlos Slim de la Salud;   Broad Institute of Harvard and MIT
Recruiting - verified April 2014

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Condition:   Healthy
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 300 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathies
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified April 2014

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-1293;   Drug: Lantus™
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Lixisenatide AVE0010;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified April 2014

Mitochondrial nt3243 A>G Mutation in Taiwan

Conditions:   MELAS Syndrome;   Noninsulin-dependent Diabetes Mellitus With Deafness
Intervention:  
Sponsors:   National Taiwan University Hospital;   National Cheng-Kung University Hospital
Recruiting - verified April 2014

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo to Ertugliflozin;   Other: Glimepiride;   Drug: Placebo to Glimepiride;   Biological: Basal Insulin;   Drug: Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status

Condition:   Obesity
Intervention:   Drug: Exenatide
Sponsor:   Shanghai 10th People's Hospital
Not yet recruiting - verified December 2013

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified April 2014

Group Appointments in Primary Care: A Clinical Group Education Intervention To Improve Diabetes Outcomes

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Behavioral: Group Appointments;   Behavioral: Individual Appointments (IAs)
Sponsors:   University of British Columbia;   Ministry of Health, British Columbia
Recruiting - verified April 2014

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified April 2014

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified April 2014

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Condition:   Diabetic Nephropathies
Interventions:   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: BAY94-8862;   Drug: Placebo;   Drug: BAY 94-8862;   Drug: BAY 94-8862
Sponsor:   Bayer
Recruiting - verified April 2014

Trial of Exenatide for Parkinson's Disease

Condition:   Parkinson's Disease
Interventions:   Drug: Exenatide;   Other: Placebo
Sponsor:   University College, London
Not yet recruiting - verified April 2014

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Pregnant Women With and Without Gestational Diabetes Mellitus

Condition:   Diabetes, Gestational
Intervention:   Behavioral: exercise
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital
Recruiting - verified April 2014

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified April 2014

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsor:   Janssen Scientific Affairs, LLC
Recruiting - verified April 2014

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK2330672;   Drug: Placebo;   Drug: Metformin
Sponsors:   GlaxoSmithKline;   Elite Research Institute
Completed - verified April 2014

The Effectiveness of Smoking Cessation in Prediabetic Smokers

Conditions:   Diabetes Mellitus;   Cigarette Smoking;   Prediabetes
Interventions:   Other: Smoking cessation;   Behavioral: Self-management
Sponsors:   National Taiwan University Hospital;   National Science Council, Taiwan
Recruiting - verified April 2014

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: metformin;   Drug: sulfonylurea
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified April 2014

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
Sponsor:   Bayer
Not yet recruiting - verified April 2014

CARMELINA: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY2605541;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Healthy
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified April 2014

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified April 2014

A Study of LY3025876 in Participants With Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3025876;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Study Of Diabetic Nephropathy With Atrasentan

Condition:   Diabetic Nephropathy
Interventions:   Drug: Atrasentan;   Drug: Placebo
Sponsor:   AbbVie
Recruiting - verified April 2014

Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to Sitagliptin;   Drug: Open-label Metformin;   Drug: Open-label Glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.

Condition:   Type 2-diabetes
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   University of Erlangen-Nürnberg Medical School
Completed - verified April 2014

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Metformin XR
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified April 2014

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified April 2014

MARLINA - T2DM : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin 5mg
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773 Placebo;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

Comparison of Insulin Mix25 Versus Mix50

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin Lispro Mix25;   Drug: Insulin Lispro Mix50
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo;   Drug: Dulaglutide;   Drug: Glimepiride
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: lixisenatide (AVE0010);   Drug: insulin glulisine (HMR1964)
Sponsor:   Sanofi
Recruiting - verified April 2014

Validation of an RLIP76 Assay in Humans

Condition:   Type 2 Diabetes
Intervention:   Other: Blood Draw
Sponsor:   City of Hope Medical Center
Recruiting - verified April 2014

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo;   Drug: Empagliflozin + Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

User Evaluation of the MiniMed 620G and 640G Insulin Pumps

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Medtronic MiniMed 620G or 640G Insulin Pump
Sponsor:   Medtronic Diabetes
Recruiting - verified November 2013

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Hyperglycemia
Interventions:   Drug: Empagliflozin low dose qd;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose qd;   Drug: Empagliflozin low dose bid;   Drug: Metformin 500 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Empagliflozin low dose bid;   Drug: Metformin 1000 mg bid;   Drug: Metformin 500 mg bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid;   Drug: Metformin 1000 mg bid;   Drug: Empagliflozin high dose bid
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified April 2014

A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

Condition:   Diabetic Nephropathy
Interventions:   Drug: PF-04634817;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified April 2014

Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313 AM1)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin;   Drug: Sitagliptin;   Drug: Acarbose;   Drug: Repaglinide;   Drug: Glimepiride;   Drug: Gliclazide
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3012;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

MK-3102 Phase III Clinical Trial - Placebo- and Sitagliptin-controlled Monotherapy Study in Japanese Participants With Type 2 Diabetes Mellitis (MK-3102-020)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Sitagliptin;   Drug: Placebo to MK-3102;   Drug: Placebo to sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Almased Multi-Center Diabetes Intervention Trial

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Dietary Supplement: Almased Meal Replacement Powder;   Behavioral: Group-Based Lifestyle Intervention
Sponsors:   Wake Forest School of Medicine;   University of Freiburg;   University of Campinas, Brazil;   London Metropolitan University;   University of Mysore, India
Active, not recruiting - verified April 2014

Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Metabolic Syndrome
Interventions:   Dietary Supplement: 1 gram of White Korean Ginseng;   Dietary Supplement: 3 grams of White Korean Ginseng;   Dietary Supplement: 6 grams of White Korean Ginseng;   Dietary Supplement: 3 grams of Wheat Bran Control;   Dietary Supplement: 500mg of Korean Red Ginseng
Sponsor:   St. Michael's Hospital, Toronto
Completed - verified April 2014

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

MK-3102 Phase III Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015 AM1)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Basal medication
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified April 2014

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine new formulation (HOE901);   Drug: Insulin glargine (HOE901)
Sponsor:   Sanofi
Completed - verified April 2014

A Study of Dulaglutide in Chinese Participants

Conditions:   Diabetes Mellitus, Type 2;   Healthy Volunteers
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

Resistance Training and Testosterone After Spinal Cord Injury

Condition:   Spinal Cord Injury
Interventions:   Procedure: Resistance Training and Testosterone Patches;   Drug: Testosterone Patches
Sponsors:   Department of Veterans Affairs;   Virginia Commonwealth University
Recruiting - verified April 2014

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Vitamin D3;   Drug: Omega-3 fatty acid (fish oil);   Dietary Supplement: Vitamin D3 placebo;   Drug: Fish oil placebo
Sponsors:   Brigham and Women's Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified April 2014

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus

Condition:   Hepatitis B
Intervention:   Biological: Engerix™-B
Sponsor:   GlaxoSmithKline
Completed - verified February 2014

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified April 2014

An Educational Intervention for Type 2 Diabetes Patients

Condition:   Diabetes Mellitus
Interventions:   Behavioral: Intervention Video;   Behavioral: Control
Sponsor:   Department of Veterans Affairs
Recruiting - verified April 2014

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Vildagliptin
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2014

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296 AM1)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin/metformin XR;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

Safety and Efficacy of YH14617 in Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: YH14617;   Drug: YH14617;   Drug: YH14617;   Drug: Placebo
Sponsors:   Yuhan Corporation;   Peptron, Inc.
Recruiting - verified April 2014

Study to Assess Safety & Efficacy of Sitagliptin as Initial Monotherapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Metformin Rescue;   Drug: Sitagliptin Rescue;   Biological: Insulin Rescue
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified April 2014

"Effect of High Fat and High Glycemic Diets

Condition:   Type 2 Diabetes
Interventions:   Behavioral: High Glycemic Diet;   Behavioral: Control diet
Sponsor:   Mayo Clinic
Recruiting - verified April 2014

Orthogonal Polarisation Study in Young, Elderly and Type 2 Diabetics

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Glucose;   Dietary Supplement: Placebo
Sponsor:   Maastricht University Medical Center
Completed - verified April 2014

Identification and Characterization of Monogenic Diabetes

Condition:   Diabetes
Interventions:   Other: Constitution of a biological bank;   Other: Metabolic studies
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified April 2014

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: ITCA 650 60 mcg/day;   Drug: sitagliptin
Sponsor:   Intarcia Therapeutics
Recruiting - verified April 2014

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

Condition:   Type 2 Diabetes
Interventions:   Drug: ITCA 650;   Other: ITCA placebo
Sponsor:   Intarcia Therapeutics
Recruiting - verified April 2014

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

Diet and Systemic Inflammation

Conditions:   Low-grade Chronic Inflammation;   Intestinal Permeability;   Type 2 Diabetes Mellitus;   Cardiovascular Disease;   Obesity
Interventions:   Other: Fructose-sweetened beverages;   Other: Glucose-sweetened beverages;   Other: High-fructose corn syrup-sweetened beverages
Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   University of Washington
Completed - verified April 2014

Technology-assisted Case Management in Adults With Type 2 Diabetes

Condition:   Diabetes
Intervention:   Device: Technology-Assisted Case Management (TACM with the FORA 2-in-1 Telehealth System)
Sponsors:   Medical University of South Carolina;   Department of Defense
Active, not recruiting - verified May 2013

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (HOE901);   Drug: INSULIN GLULISINE (HMR1964)
Sponsor:   Sanofi
Recruiting - verified April 2014

Local Measures to Prevent Diabetes in the Værnes Region.

Conditions:   Diabetes Mellitus Type 2;   Obesity
Intervention:   Behavioral: Behavioural change programme
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified April 2014

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Intensive insulin;   Drug: Routine Care
Sponsors:   Ohio University;   Western University of Health Sciences
Completed - verified April 2014

Genetic Testing for Type 2 Diabetes

Condition:   Diabetes Mellitus
Interventions:   Genetic: genetic testing for type 2 diabetes;   Other: Conventional risk counseling for type 2 diabetes
Sponsors:   Department of Veterans Affairs;   Duke University
Completed - verified April 2014

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: taspoglutide;   Drug: insulin glargine;   Drug: metformin
Sponsor:   Hoffmann-La Roche
Terminated - verified April 2014

High Blood Pressure and Sleep Apnea in Diabetic Macular Edema

Condition:   Diabetic Retinopathy
Interventions:   Behavioral: high blood pressure treatment;   Behavioral: sleep apnea treatment;   Behavioral: diabetic macular edema treatment
Sponsor:   Assistance Publique - Hôpitaux de Paris
Completed - verified April 2014

Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   The George Institute;   Servier
Completed - verified April 2014

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Standardized Risk Assessment
Sponsors:   Duke University;   deCODE genetics
Completed - verified April 2014

The VA Diabetes Trial Follow-up Study (VADT-FS)

Conditions:   Diabetes;   Glycemic Control
Intervention:  
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified April 2014

GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lixisenatide (AVE0010);   Device: Pen auto-injector;   Drug: Exenatide;   Device: Prefilled pen injector;   Drug: Metformin
Sponsor:   Sanofi
Completed - verified April 2014

Pharmacist-led Group Medical Visits to Help With Diabetes Management

Conditions:   Diabetes Mellitus;   Cardiovascular Diseases
Interventions:   Other: Algorithm driven medication titration;   Behavioral: Monitoring;   Behavioral: Group support;   Behavioral: Self efficacy
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Inflammation;   Insulin Resistance;   Noninsulin-dependent Diabetes Mellitus
Interventions:   Drug: Salsalate;   Drug: Placebo
Sponsors:   Department of Veterans Affairs;   Joslin Diabetes Center
Completed - verified April 2014

Insulin Treatment Variation in Southwestern Diabetics

Conditions:   Diabetes;   Self-Monitoring, Blood Glucose
Intervention:  
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Diabetes Telemedicine Project

Conditions:   Diabetes Mellitus Type 2;   Diabetes Mellitus, Type 1
Interventions:   Behavioral: The Diabetes Treatment Satisfaction Questionnaire;   Behavioral: Diabetes Empowerment Scale;   Behavioral: CBOC's undergo half-day joint-clinics via teleconference
Sponsor:   Department of Veterans Affairs
Completed - verified April 2014

Get CardioSmart

You're Invited